Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine

WHITEHOUSE STATION, N.J. — Merck, known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar. Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack.

“There are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have a recurrent heart attack, so there remains a need for additional treatment options,” said Dr. Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. “The results of today’s Advisory Committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack. We look forward to working with the FDA as it completes its review.”

The FDA is not bound by the Committee’s guidance, but takes its advice into consideration when reviewing investigational medicines.

About Vorapaxar>

Vorapaxar, proposed trade name ZONTIVITY™, is a first-in-class protease-activated receptor-1 (PAR-1) antagonist designed to inhibit the formation of blood clots. PAR-1 is a receptor activated by thrombin, known to be a potent platelet activator. Vorapaxar inhibits thrombin-induced platelet aggregation by inhibiting PAR-1 receptors on platelets.

Data supporting the filing of this new drug application are from the 26,449 patient TRA 2°P - TIMI 50 trial, a randomized, double-blind, placebo-controlled study of vorapaxar used in addition to standard therapy including other antiplatelet agents. Patients included in the study had a history of myocardial infarction, ischemic stroke, or peripheral artery disease and had a median follow-up of 2.5 years.